Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study

Abstract Background Emerging evidence indicates that estrogen receptor-low (ER-low)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) may more closely resemble ER-negative (ER-zero, < 1%) rather than ER-positive disease in terms of biological and clinicopathological charac...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sanna Steen, Emelie Karlsson, Ida Björnheden, Gunilla Rask, Viktoria Thurfjell, Hampus Nobin, Blanka Kolodziej, Anna Bodén, Annette Bauer, Rickard Einefors, Per Nilsson, Ioannis Zerdes, Andri Papakonstantinou, Theodoros Foukakis, Irma Fredriksson, Mattias Rantalainen, Eugenia Colón-Cervantes, Anikó Kovács, Balazs Acs, Johan Hartman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-11-01
Serie:	Breast Cancer Research
Soggetti:	Triple negative breast cancer Neoadjuvant immunotherapy Pembrolizumab ER low
Accesso online:	https://doi.org/10.1186/s13058-025-02179-3
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!